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Abstracts / Biol Blood Marrow Transplant 21 (2015) S206eS239 S225immunosuppressants at 2 yrs post transplant). Two patients
experienced graft failure within three months and a third
one within 14 months post transplant (two of whom
underwent successful second transplants 12 mos and
18 mos later while the third elected to not undergo
retransplantation and is now transfusion dependent). 6
patients became durably engrafted and remain disease-free.
Since 3 of the 9 patients rejected their grafts, the
conditioning regimen was modiﬁed to include the same
three agents but with alemtuzumab given between days -21
and -19. Results in ﬁve subsequent pts have yielded no
instances of graft rejection. Due to its relatively long half-life
(15-21 days), alemtuzumab, when given close to the day of
stemcell infusion,mayreduce the likelihoodof acuteGvHDbut
may also lead to in-vivo T-cell depletion of the donor graft,
thereby increasing the probability of graft loss. In this small
study, this latter effect outweighed the possible beneﬁt of
reducing the likelihoodof acuteGvHD.Thismaybeparticularly
true in this patient populationwhich comes to transplantation
with an intact, and often sensitized, immune system.303
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Background: Rare diseases requiring hematopoietic stem
cell transplantation present a challenge for pediatric BMT
centers. The patients present at a low frequency, and there
are often no established conditioning regimens for these
disorders. We report the conditioning regimen, donor
source, and outcomes for the following rare disorders
transplanted at our program from January 2011 through
January 2014. During the past three years we have had pa-
tients present with the following: Fanconi anemia (FA),
Hemophagocytic Lymphohistiocytosis (HLH), Congenital
Amegakaryocytic Thrombocytopenia (CAMT), Chediak-
Higashi Syndrome (CHS), Langerhans Cell Histiocytosis
(LCH), Beta-thalassemia, Juvenile Myelomonocytic Leukemia
(JMML), Immunodeﬁciency Syndrome with Myelodysplastic
Syndrome (IDS/MDS), and Cartilage Hair Hypoplasia (CHH).
Methods: We are the sole pediatric HSCT center in our state.
We treat patients with rare disorders that require HSCT at
our center, and are reporting the management strategy and
outcomes for this wide variety of rare disorders.Table 1
Patient characteristics and outcomes for patients with rare disorders.
Patient Disease Donor / HLA Match Conditioning
1 HLH UCB- 5/6 Bu/VP/CY/ATG
2 HLH MSD BM- 10/10 Alem/Flu/Mel
3 FA BM- 10/10 TBI/Flu/CY/ATG
4 B-thal MRD BM- 8/10 Bu/CY/ATG
5 IDS/MDS BM- 9/10 Bu/CY/ATG
6 LCH MSD BM- 10/10 Alem/Flu/Mel
7 CHH MSD UCB- 6/6 Bu/CY/ATG
8 JMML MSD BM- 10/10 Bu/CY/Mel
9 CAMT BM- 10/10 CY/ATG/TBI
10 HLH BM- 9/10 Alem/Flu/Mel
11 CHS BM- 10/10 Bu/CYResults: The patients were referred to or diagnosed at our
institution from January 2011 to January 2014. All patients
were transplanted with the best available donor using bone
marrow (BM) or umbilical cord blood (UCB). Conditioning
regimens and treatment plans were determined by the BMT
attending team based on reviews of the literature and varied
with type of disease. The BMT coordinators and nurse prac-
titioners were educated about the disorders and then
educated the inpatient and outpatient teams. The PharmD
created order sets for patients based on the treatment plans.
Patient characteristics and outcomes are presented in Table 1.
The day 100 survival was 100%. Nine of 11 patients are alive
and well (A/W) with no evidence of disease.
Conclusions: Our program has treated a variety of rare disor-
ders with a > 80% Event-Free-Survival. Our data suggests that
excellent outcomes can be obtained at small-moderate sized
BMT programs when the team approach is used to create the
best-practices plan of care for each individual patient.304
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Background: TMA with high-risk features at diagnosis,
including terminal complement activation measured by
elevated sC5b-9 and proteinuria, is associated with very
high mortality as <20% of such untreated patients survive
at 1 year after HSCT (Jodele et al, Blood 2014). In a thera-
peutic pilot study, we observed TMA resolution in 4 of
6 patients with high-risk TMA who achieved complement
blockade using eculizumab, with dosing guided pharma-
codynamically by measurement of total hemolytic
complement activity (CH50) (Jodele et al, BBMT 2014). We
now present an expanded patient cohort treated with
eculizumab.ANC > 500 (Day) Platelet > 20K (Day) Outcome
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